Developer docs
API playgroundTry for free, no card

Search company profiles

Hester Biosciences

Full company profile

uuid0005i4q

Namestring
Hester Biosciences
Legal namestring
Hester Biosciences Limited
Company typeenum
Public
Founded yearint
1987
Descriptiontext

Hester Biosciences Limited is one of India's largest animal healthcare companies and the country's second largest poultry vaccine manufacturer, founded in 1987 by Rajiv Gandhi. The company manufactures vaccines, medicines, and healthcare products across three core segments — Poultry Healthcare, Animal Healthcare, and Pet Care — plus a Diagnostic Labs service line. It operates as Asia's largest one-stop animal biological manufacturing facility, with three owned plants in India (6.25 billion doses), Nepal (1.24 billion doses), and Tanzania (1.50 billion doses), and reaches 35+ countries through 900+ distributors. The product portfolio includes inactivated avian influenza (H9N2), small ruminant combination vaccines developed under the GALVmed VITAL project, and Covaxin drug substance contract-manufactured for Bharat Biotech under a Rs 60 crore BIRAC grant.

The company earns revenue primarily through one-time B2B sales of biological products to its distributor network across India, Nepal, Tanzania, and 35+ additional emerging markets, supplemented by professional services contract manufacturing for Bharat Biotech. Pricing is quote-based for distributors and institutional buyers rather than publicly disclosed. In FY26, revenue grew 7% to INR 3,325.99 million while consolidated profit after tax jumped 99% to INR 574.84 million, with the Poultry Healthcare division up 24%. Recent strategic actions include FDCA approval and launch of the H9N2 vaccine, capitalization of fill-finish and BSL-3 facilities to double drug product capacity, entry into Egypt via a Novapharma distribution partnership, and the partial divestment of Texas Lifesciences. The company is publicly listed on Indian exchanges (NSE: HESTERBIO) with no identified controlling parent entity.

Short descriptiontext

Hester Biosciences Limited is an Indian public animal biologicals manufacturer — Asia's largest one-stop facility — producing vaccines and healthcare products for poultry, livestock, and pets across 35+ countries via 900+ distributors and three plants in India, Nepal, and Tanzania.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
251–500
akta.pro rankint
HeadquartersSan Diego, United States
HQ citystring
San Diego
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
animal vaccines, poultry healthcare, veterinary biologicals, livestock vaccines, pet care vaccines
Industry4 codes
1Veterinary Vaccines (Biologics)
CodeHLAMAEALPrimaryYes
2Vaccine Manufacturing & Contract Services (Veterinary Vaccine CDMO)
CodeHLAMAKAIPrimaryNo
3Livestock Vaccines (Cattle, Swine, Sheep & Goats)
CodeHLAMAKABPrimaryNo
4Companion Animal Vaccines (Dogs & Cats)
CodeHLAMAKAAPrimaryNo
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Biological Products, (No Disgnostic Substances)2836
Product category
Animal Vaccines
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model4 records
1Poultry Healthcare Products
TypeOne Time License
Description

Vaccines and healthcare products for poultry birds, including the H9N2 Avian Influenza vaccine, representing a primary revenue driver with 24% revenue increase in FY26

scanx.trade
2Animal Healthcare Products
TypeOne Time License
Description

Healthcare products for livestock animals including vaccines for small ruminants

hester.in
3Pet Care Products
TypeOne Time License
Description

Healthcare products for pets including vaccines and medicines

hester.in
4Contract Manufacturing
TypeProfessional Services
Description

Manufacturing Covaxin drug substance for Bharat Biotech under BIRAC grant of Rs 60 crore

economictimes.indiatimes.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Operations, Supply Chain, Personnel, Technology or R&D, Infrastructure, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 record
1Hester Biosciences Africa Limited
Description

Subsidiary focused on bridging the gap between demand and supply for animal vaccines and healthcare products in Africa

hester.in
Core offering1 text field

Hester Biosciences manufactures and markets animal vaccines and healthcare products for poultry, livestock, and companion animals, with manufacturing facilities in India, Nepal, and Tanzania producing over 9 billion doses annually. The company also performs contract manufacturing of biological drug substances (e.g., Covaxin for Bharat Biotech) and operates diagnostic laboratory services for the animal healthcare sector.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • 24% revenue increase in Poultry Healthcare division in FY26
+4 more records
Product overview1 text field

Hester Biosciences is one of India's leading animal healthcare companies and the second largest poultry vaccine manufacturer in the country. The company operates as Asia's largest one-stop animal biological manufacturing facility, offering an integrated portfolio across Poultry Healthcare, Animal Healthcare, Pet Care, and Diagnostic Labs. The product portfolio includes vaccines (Poultry, Animal, Pet Care, and specific vaccines like H9N2 Avian Influenza and Small Ruminant Combination Vaccine) and health products. The company has manufacturing plants in India (6.25 billion doses), Nepal (1.24 billion doses), and Tanzania (1.50 billion doses), with strategic presence across 35+ countries.

Product and service8 records
1Poultry Healthcare
CategoryAnimal Vaccines
Description

Comprehensive vaccine and healthcare product portfolio for poultry birds, including vaccines for various poultry diseases such as avian influenza. Targets commercial poultry farmers, poultry integrators, and layer/broiler operations.

2Animal Healthcare
CategoryAnimal Vaccines
Description

Vaccines and healthcare products for livestock animals including sheep, goats, and other domesticated animals, addressing disease prevention in developing markets.

3Pet Care
CategoryAnimal Vaccines
Description

Healthcare products and vaccines designed for companion animals including dogs and cats, supporting preventive healthcare for the rising pet ownership segment.

4Diagnostic Labs
CategoryVeterinary Diagnostic Services
Description

Laboratory diagnostic services offering end-to-end solutions for customers in animal healthcare, supporting disease detection and flock/herd health management.

5H9N2 Avian Influenza Vaccine
CategoryAnimal Vaccines
Description

Inactivated avian influenza vaccine targeting the H9N2 strain for poultry, addressing year-round comorbidity, egg production drops in layers, and performance loss in broilers.

6Small Ruminant Combination Vaccine
CategoryAnimal Vaccines
Description

Three-in-one vaccine protecting sheep and goats against Contagious Caprine Pleuropneumonia, Sheep and Goat Pox, and Peste des Petits Ruminants, developed under GALVmed's VITAL project.

7Covaxin Drug Substance
CategoryContract Manufacturing (Human Vaccine)
Description

COVID-19 vaccine (Covaxin) drug substance manufactured for Bharat Biotech under BIRAC grant, with fill-finish operations handled by Bharat Biotech.

8Health Products
CategoryAnimal Healthcare Products
Description

Pharmaceutical and health products complementing the vaccine portfolio for animal healthcare applications across poultry, livestock, and pet care segments.

Scale indicator14 records

Each record includes

Type, Value, Description, Source

Partnership6 partners
1Ticop Life
Strategic tierMinorTypeOthersAnnounced on2026-03-11
Description

Acquisition of 43.81% stake in Texas Lifesciences divested to Ticop Life for Rs 9.2 crore. Hester maintains 11% stake and continues business relations.

business-standard.com
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Partnership as part of VITAL project for developing combination vaccines for small ruminants. Four other combination vaccines developed by Hester are undergoing regulatory review as part of the initiative.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Long-standing organizational partner in business operations.

Strategic tierMinorTypeChannel Partner/ Reseller/ Distributor
Description

Latest partnership for foray into Egyptian market for distribution of animal healthcare products.

Strategic tierCoreTypeTechnology or Integration
Description

Technology acquired from ICAR-NIHSAD via Agrinnovate India for H9N2 Avian Influenza vaccine manufacturing, marking key regulatory milestone.

Strategic tierMajorTypeChannel Partner/ Reseller/ Distributor
Description

Hester supplies Covaxin drug substance to Bharat Biotech, which handles fill-finish at its facilities. Monthly production of 5-7 million doses.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeRegional player
Description

Indian integrated poultry company with animal health products, overlapping with Hester's poultry vaccine segment in India. Less specialized than Hester in pure biologics but addresses the same customer base.

TypeDirect peer
Description

Indian animal vaccine manufacturer owned by the National Dairy Development Board, producing vaccines for livestock, poultry, and companion animals. Direct competitor in the Indian veterinary vaccine market with overlapping product portfolios and B2B distribution models.

TypeBroad incumbent
Description

US-listed animal health and nutrition company with vaccines, parasiticides, and nutritional specialties for livestock and poultry. Comparable in product categories and emerging-market distribution focus, though broader portfolio.

TypeBroad incumbent
Description

Global animal health company with a portfolio spanning vaccines, parasiticides, and therapeutics for livestock and pets. Comparable across product categories and B2B distribution model, though focused on developed markets.

TypeDirect peer
Description

Specialist Indian poultry vaccine manufacturer that directly competes with Hester in the poultry vaccine category across India and select export markets. Closely comparable in product mix, scale, and customer base.

TypeBroad incumbent
Description

Global leader in animal health and vaccines, offering a comprehensive portfolio across livestock, poultry, and companion animals. Comparable business model and product categories, but with far broader geographic reach and higher-margin developed-market exposure.

TypeBroad incumbent
Description

Division of Merck offering vaccines and pharmaceuticals across all major animal segments globally. Comparable in biologicals manufacturing capability and vaccine pipeline, though at significantly greater scale and global footprint.

TypeBroad incumbent
Description

French multinational animal health company specializing in vaccines and pharmaceutical products for livestock, poultry, and companion animals. Comparable in vaccine manufacturing and emerging-market distribution, especially in Africa and Asia.

TypeEmerging player
Description

South African animal vaccine manufacturer focused on livestock and poultry vaccines for the African market. Comparable developing-market positioning to Hester's Tanzania operations and similar product mix.

TypeBroad incumbent
Description

Major global animal health player with a strong biologicals and vaccines franchise across livestock and pets. Directly comparable product categories including poultry and livestock vaccines.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries3 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A2 records

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Hester Biosciences

Hester Biosciences Limited is an Indian public animal biologicals manufacturer — Asia's largest one-stop facility — producing vaccines and healthcare products for poultry, livestock, and pets across 35+ countries via 900+ distributors and three plants in India, Nepal, and Tanzania.

What Hester Biosciences does

Hester Biosciences Limited is one of India's largest animal healthcare companies and the country's second largest poultry vaccine manufacturer, founded in 1987 by Rajiv Gandhi. The company manufactures vaccines, medicines, and healthcare products across three core segments — Poultry Healthcare, Animal Healthcare, and Pet Care — plus a Diagnostic Labs service line. It operates as Asia's largest one-stop animal biological manufacturing facility, with three owned plants in India (6.25 billion doses), Nepal (1.24 billion doses), and Tanzania (1.50 billion doses), and reaches 35+ countries through 900+ distributors. The product portfolio includes inactivated avian influenza (H9N2), small ruminant combination vaccines developed under the GALVmed VITAL project, and Covaxin drug substance contract-manufactured for Bharat Biotech under a Rs 60 crore BIRAC grant.

The company earns revenue primarily through one-time B2B sales of biological products to its distributor network across India, Nepal, Tanzania, and 35+ additional emerging markets, supplemented by professional services contract manufacturing for Bharat Biotech. Pricing is quote-based for distributors and institutional buyers rather than publicly disclosed. In FY26, revenue grew 7% to INR 3,325.99 million while consolidated profit after tax jumped 99% to INR 574.84 million, with the Poultry Healthcare division up 24%. Recent strategic actions include FDCA approval and launch of the H9N2 vaccine, capitalization of fill-finish and BSL-3 facilities to double drug product capacity, entry into Egypt via a Novapharma distribution partnership, and the partial divestment of Texas Lifesciences. The company is publicly listed on Indian exchanges (NSE: HESTERBIO) with no identified controlling parent entity.

Hester Biosciences firmographics

Firmographics
Name
Hester Biosciences
Legal name
Hester Biosciences Limited
Website
https://hesterbiosciences.co.in
Company type
Public
Founded year
1987
Operating status
Operating
Headcount range
251–500 employees
Short description
Hester Biosciences Limited is an Indian public animal biologicals manufacturer — Asia's largest one-stop facility — producing vaccines and healthcare products for poultry, livestock, and pets across 35+ countries via 900+ distributors and three plants in India, Nepal, and Tanzania.
Ownership category
akta.pro rank

Hester Biosciences industry classification

Industry
Product category
Animal Vaccines
SIC
Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)
akta.pro primary industry
Veterinary Vaccines (Biologics) (HLAMAEAL)
akta.pro secondary industries
Vaccine Manufacturing & Contract Services (Veterinary Vaccine CDMO) (HLAMAKAI), Livestock Vaccines (Cattle, Swine, Sheep & Goats) (HLAMAKAB), Companion Animal Vaccines (Dogs & Cats) (HLAMAKAA)

Keywords

  • Animal vaccines
  • Poultry healthcare
  • Veterinary biologicals
  • Livestock vaccines
  • Pet care vaccines

Where Hester Biosciences is headquartered

Location

Headquarters

HQ city
San Diego
HQ country
United States
HQ region
North America

Offices3 records

Markets served

Hester Biosciences business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Operations, Supply Chain, Personnel, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

  1. Poultry Healthcare Products: Vaccines and healthcare products for poultry birds, including the H9N2 Avian Influenza vaccine, representing a primary revenue driver with 24% revenue increase in FY26
  2. Animal Healthcare Products: Healthcare products for livestock animals including vaccines for small ruminants
  3. Pet Care Products: Healthcare products for pets including vaccines and medicines
  4. Contract Manufacturing: Manufacturing Covaxin drug substance for Bharat Biotech under BIRAC grant of Rs 60 crore

Go-to-market motion1 record

Distribution channels2 records

Marketing channels3 records

Hester Biosciences product offering

Product offering

Core offering

Hester Biosciences manufactures and markets animal vaccines and healthcare products for poultry, livestock, and companion animals, with manufacturing facilities in India, Nepal, and Tanzania producing over 9 billion doses annually. The company also performs contract manufacturing of biological drug substances (e.g., Covaxin for Bharat Biotech) and operates diagnostic laboratory services for the animal healthcare sector.

Product overview

Hester Biosciences is one of India's leading animal healthcare companies and the second largest poultry vaccine manufacturer in the country. The company operates as Asia's largest one-stop animal biological manufacturing facility, offering an integrated portfolio across Poultry Healthcare, Animal Healthcare, Pet Care, and Diagnostic Labs. The product portfolio includes vaccines (Poultry, Animal, Pet Care, and specific vaccines like H9N2 Avian Influenza and Small Ruminant Combination Vaccine) and health products. The company has manufacturing plants in India (6.25 billion doses), Nepal (1.24 billion doses), and Tanzania (1.50 billion doses), with strategic presence across 35+ countries.

Differentiator

Problem solved

Functional benefit

Brands

  • Hester Biosciences Africa Limited: Subsidiary focused on bridging the gap between demand and supply for animal vaccines and healthcare products in Africa

Products and services

  • Poultry Healthcare Comprehensive vaccine and healthcare product portfolio for poultry birds, including vaccines for various poultry diseases such as avian influenza. Targets commercial poultry farmers, poultry integrators, and layer/broiler operations.
  • Animal Healthcare Vaccines and healthcare products for livestock animals including sheep, goats, and other domesticated animals, addressing disease prevention in developing markets.
  • Pet Care Healthcare products and vaccines designed for companion animals including dogs and cats, supporting preventive healthcare for the rising pet ownership segment.
  • Diagnostic Labs Laboratory diagnostic services offering end-to-end solutions for customers in animal healthcare, supporting disease detection and flock/herd health management.
  • H9N2 Avian Influenza Vaccine Inactivated avian influenza vaccine targeting the H9N2 strain for poultry, addressing year-round comorbidity, egg production drops in layers, and performance loss in broilers.
  • Small Ruminant Combination Vaccine Three-in-one vaccine protecting sheep and goats against Contagious Caprine Pleuropneumonia, Sheep and Goat Pox, and Peste des Petits Ruminants, developed under GALVmed's VITAL project.
  • Covaxin Drug Substance COVID-19 vaccine (Covaxin) drug substance manufactured for Bharat Biotech under BIRAC grant, with fill-finish operations handled by Bharat Biotech.
  • Health Products Pharmaceutical and health products complementing the vaccine portfolio for animal healthcare applications across poultry, livestock, and pet care segments.

Quantifiable outcome

  • 24% revenue increase in Poultry Healthcare division in FY26
  • +4 more outcomes

Companies that use Hester Biosciences

Customer profile

Named customers1 record

Segments3 records

Ideal customer profiles3 records

Hester Biosciences technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Hester Biosciences partnerships and signals

Strategic signal

Partnerships

Six partnerships are on record, tiered minor, core and major.

  • Ticop LifeminorOthers · 11 March 2026Acquisition of 43.81% stake in Texas Lifesciences divested to Ticop Life for Rs 9.2 crore. Hester maintains 11% stake and continues business relations.
  • GALVmed (Global Alliance for Livestock Veterinary Medicines)coreStrategic or Co-development PartnerPartnership as part of VITAL project for developing combination vaccines for small ruminants. Four other combination vaccines developed by Hester are undergoing regulatory review as part of the initiative.
  • Golchha OrganisationminorStrategic or Co-development PartnerLong-standing organizational partner in business operations.
  • NovapharmaminorChannel Partner/ Reseller/ DistributorLatest partnership for foray into Egyptian market for distribution of animal healthcare products.
  • ICAR-NIHSAD via Agrinnovate IndiacoreTechnology or IntegrationTechnology acquired from ICAR-NIHSAD via Agrinnovate India for H9N2 Avian Influenza vaccine manufacturing, marking key regulatory milestone.
  • Bharat BiotechmajorChannel Partner/ Reseller/ DistributorHester supplies Covaxin drug substance to Bharat Biotech, which handles fill-finish at its facilities. Monthly production of 5-7 million doses.

Scale indicators14 records

Recent moves7 records

Expansion highlights4 records

Hester Biosciences competitors and assessment

Company assessment

Regional players

  • Venkys (VH Group): Indian integrated poultry company with animal health products, overlapping with Hester's poultry vaccine segment in India. Less specialized than Hester in pure biologics but addresses the same customer base.

Direct peers

  • Indian Immunologicals Limited: Indian animal vaccine manufacturer owned by the National Dairy Development Board, producing vaccines for livestock, poultry, and companion animals. Direct competitor in the Indian veterinary vaccine market with overlapping product portfolios and B2B distribution models.
  • Indovax: Specialist Indian poultry vaccine manufacturer that directly competes with Hester in the poultry vaccine category across India and select export markets. Closely comparable in product mix, scale, and customer base.

Broad incumbents

  • Phibro Animal Health: US-listed animal health and nutrition company with vaccines, parasiticides, and nutritional specialties for livestock and poultry. Comparable in product categories and emerging-market distribution focus, though broader portfolio.
  • Elanco Animal Health: Global animal health company with a portfolio spanning vaccines, parasiticides, and therapeutics for livestock and pets. Comparable across product categories and B2B distribution model, though focused on developed markets.
  • Zoetis: Global leader in animal health and vaccines, offering a comprehensive portfolio across livestock, poultry, and companion animals. Comparable business model and product categories, but with far broader geographic reach and higher-margin developed-market exposure.
  • MSD Animal Health (Merck Animal Health): Division of Merck offering vaccines and pharmaceuticals across all major animal segments globally. Comparable in biologicals manufacturing capability and vaccine pipeline, though at significantly greater scale and global footprint.
  • Ceva Santé Animale: French multinational animal health company specializing in vaccines and pharmaceutical products for livestock, poultry, and companion animals. Comparable in vaccine manufacturing and emerging-market distribution, especially in Africa and Asia.
  • Boehringer Ingelheim Animal Health: Major global animal health player with a strong biologicals and vaccines franchise across livestock and pets. Directly comparable product categories including poultry and livestock vaccines.

Emerging players

  • Biovac: South African animal vaccine manufacturer focused on livestock and poultry vaccines for the African market. Comparable developing-market positioning to Hester's Tanzania operations and similar product mix.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

Hester Biosciences social profiles

Digital presence

Hester Biosciences financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Hester Biosciences leadership team

Management profile

Number of profiles

Profiles1 record

Hester Biosciences subsidiaries and ownership

Company hierarchy

Subsidiaries3 records

Hester Biosciences funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Hester Biosciences M&A and investment

M&A and investment

M&A2 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Hester Biosciences

What does Hester Biosciences do?

Hester Biosciences manufactures and markets animal vaccines and healthcare products for poultry, livestock, and companion animals, with manufacturing facilities in India, Nepal, and Tanzania producing over 9 billion doses annually. The company also performs contract manufacturing of biological drug substances (e.g., Covaxin for Bharat Biotech) and operates diagnostic laboratory services for the animal healthcare sector.

Is Hester Biosciences a public or private company?

Hester Biosciences is a public company. It is classified as public and is currently operating.

When was Hester Biosciences founded?

Hester Biosciences was founded in 1987. It employs 251 to 500 people.

Where is Hester Biosciences based?

Hester Biosciences is headquartered in San Diego, United States, in the North America region.

How does Hester Biosciences make money?

Four revenue lines are on record. Poultry Healthcare Products are the primary driver. The others are animal Healthcare Products, pet Care Products and contract Manufacturing.

Who are Hester Biosciences's main competitors?

Venkys (VH Group) is listed as a regional player. Direct peers are Indian Immunologicals Limited and Indovax. Broad incumbents are Phibro Animal Health, Elanco Animal Health, Zoetis, MSD Animal Health (Merck Animal Health), Ceva Santé Animale and Boehringer Ingelheim Animal Health. Biovac is listed as an emerging player.

Does Hester Biosciences have an API?

No public API is recorded for Hester Biosciences.

What industry is Hester Biosciences in?

Hester Biosciences's product category is Animal Vaccines. Its primary akta.pro industry code is HLAMAEAL, Veterinary Vaccines (Biologics), with a secondary code of HLAMAKAI, Vaccine Manufacturing & Contract Services (Veterinary Vaccine CDMO). Its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
ScanXHester Biosciences approves ₹10.50 million investment in Slyce Agri WorldHester Biosciences approved up to ₹10.50 million investment in Slyce Agri World LLP for renewable energy, representing a 26% stake in fixed capital. The cash consideration will be paid in tranches within six months, and the investment supports a Power Purchase Agreement to fulfill captive power regulations.ScanXHester Biosciences reclassifies Ravin and Bela Gandhi to public categoryHester Biosciences Ltd has successfully reclassified Ravin Gandhi and Bela Gandhi from the Promoter Group to the Public category after receiving no-objection approvals from NSE and BSE on July 24, 2026. The reclassification, governed by SEBI LODR Regulation 31A, changes the regulatory classification of their holdings, affecting public float calculations and future disclosure requirements. The company filed the final intimation on July 25, 2026, completing the process initiated in May 2026.Business TodayUTI AMC, SAMIL, ABREL, Motherson Sumi Wiring shares set to turn ex dividend todayMultiple stocks including UTI Asset Management Company Ltd, Samvardhana Motherson International Ltd, Motherson Sumi Wiring India Ltd, Aditya Birla Real Estate Ltd, Hester Biosciences Ltd, and Supreme Petrochem Ltd will turn ex-dividend on July 14, 2026, with record dates set for determining eligible shareholders. The article lists dividend amounts ranging from Rs 0.05 to Rs 40 per share across 13 companies, with actual dividend payments scheduled for August 2026. This is a routine market notification providing investors with ex-dividend schedule details for corporate dividend distributions.Business StandardHester Biosciences Ltd leads gainers in 'B' groupHester Biosciences Ltd led gainers in the BSE's 'B' group on July 13, 2026, surging 20% to Rs 2531.25 with trading volume of 21,183 shares against an average daily volume of 859 shares. Shardul Securities Ltd, BF Utilities Ltd, BCL Industries Ltd, and Indian Hume Pipe Company Ltd followed as the other top gainers in the segment, with gains ranging from 12.20% to 19.99%. The article provides routine intraday stock price and volume data for these five companies on the Bombay Stock Exchange.ScanXHester Biosciences Exits Texas Lifesciences, Sells 11% Stake for INR 23 MillionHester Biosciences Limited completed the sale of its full 11% equity stake in Texas Lifesciences Private Limited for INR 23 million on July 8, 2026, transferring 543,248 shares to existing shareholders. The transaction, approved by the Board of Directors and disclosed under SEBI Listing Regulations, marks a complete exit, reducing the company's holding in Texas Lifesciences to nil. The proceeds from the divestment are being utilized by Hester Biosciences for undisclosed purposes.ScanXHester Biosciences corrects Executive Director salary to INR 10 lakhHester Biosciences corrected the gross salary for Executive Director Ms. Priya Gandhi to INR 10 lakh per month in its 39th AGM notice. The AGM scheduled for July 21, 2026, will also consider a dividend of INR 11 per share and the ratification of the Cost Auditor's fees. The company reported a net profit of INR 521 million for FY26.ScanXHester Biosciences reports BRSR for FY26 with zero safety incidentsHester Biosciences Limited filed its Business Responsibility and Sustainability Report for FY26, reporting reduced energy consumption of 53.09 Tera Joules and GHG emissions of 8,626 metric tonnes alongside zero safety incidents. The company achieved 100% sustainable sourcing from critical suppliers and improved water withdrawal metrics, with social indicators showing 100% retention rates for parental leave and comprehensive workforce training coverage.ScanXHester Biosciences FY26 profit jumps 99% to INR 574.84 millionHester Biosciences reported a 99% increase in consolidated profit after tax to INR 574.84 million for FY26, driven by strong performance in its Poultry Healthcare division which saw a 24% revenue increase. The company's total revenue grew 7% to INR 3,325.99 million during the same period. Hester Biosciences also announced the capitalization of its Fill-Finish and BSL-3 facilities, positioning the company for future growth.ScanXHester Biosciences reports INR 521 million PAT in FY26Hester Biosciences reported a 64% rise in standalone net profit to INR 521 million for FY26, driven by improved operational efficiency. Consolidated profit after tax surged 99% to INR 574.84 million, while the Board recommended a final dividend of INR 11 per share.Business StandardHester Biosciences consolidated net profit rises 1138.76% in the March 2026 quarterHester Biosciences reported a massive 1138.76% increase in consolidated net profit to Rs 15.98 crore for the quarter ended March 2026, compared to Rs 1.29 crore in the same quarter of the previous year. Quarterly sales rose 22.19% to Rs 100.11 crore from Rs 81.93 crore year-on-year. For the full fiscal year ended March 2026, net profit grew 102.40% to Rs 55.64 crore while sales increased 6.91% to Rs 332.60 crore.